Developing Countries. With respect to final sales in DEVELOPING COUNTRIES, COMPANY shall pay to M.I.T. a running royalty of [***] Percent ([***]%) of NET SALES of LICENSED PRODUCTS and LICENSED PROCESSES by COMPANY, AFFILIATES and SUBLICENSEES in DEVELOPING COUNTRIES.
Appears in 2 contracts
Sources: Exclusive Patent License Agreement (Angion Biomedica Corp.), Exclusive Patent License Agreement (Elicio Therapeutics, Inc.)